

DIFFUSE GIANT INFLAMMATORY POLYPOSIS AT THE ONSET OF ULCERATIVE COLITIS, PRESENTING WITH PROTEIN-LOSING ENTEROPATHY AND MASQUERADING AS INTESTINAL INTUSSUSCEPTION

Elena Daniela Serban^{1,3}, P Florescu^{2,3}

Abstract

Inflammatory polyposis (IP) in ulcerative colitis (UC) appears most often over the course of the disease, being very rarely described as a presenting feature. Giant IP (> 1.5 cm in diameter or length) is very uncommon and most reported cases have had a localized form. We report a case of a male teenager, who was admitted in our clinic after 16 days of abdominal pain and bloody diarrhea. He was found with palpable abdominal mass, protein-losing enteropathy and anemia. Intestinal intussusception was considered in the surgical department; however, laparotomy did not reveal any abnormality. Readmitted to our department two months later, he was diagnosed by colonoscopy and histology with giant diffuse IP and moderate-to-severe ulcerative pancolitis. Therapy with Mesalazine and Prednisone led one month later to histological remission of the UC and reduction in the number and size of the polyps. Being a steroid-dependant UC, Azathioprine was added 3 months later and he has remained in microscopical remission since (5.6 years later). We discuss our case in relation to the literature and we emphasize the importance of mucosal healing, given also the high risk of colorectal cancer. To the best of our knowledge, this is the first case of pediatric UC presenting with giant diffuse IP at the disease onset.

Key words: giant inflammatory polyposis, ulcerative colitis, onset, protein-losing enteropathy, children

Introduction

Inflammatory polyps (or “pseudopolyps”) arise during the process of regeneration and healing of the ulcerations, in 12.5-20% patients with ulcerative colitis (UC)^{1,2}. They appear mostly during the course of the disease, very rarely being described at the disease onset¹. Giant inflammatory polyp - GIP (> 1.5 cm in length or diameter) is exceptionally rare³. Only three adult cases with GIP at the onset of the UC have been described, these all being localized forms⁴⁻⁶. To the best of our knowledge, no pediatric case with diffuse GIP as a presenting feature of the UC has been previously described. We report a case of a male teenager, who

presented with abdominal pain, bloody diarrhea, palpable abdominal mass, protein-losing enteropathy and anemia and was diagnosed with diffuse GIP and moderate-to-severe ulcerative pancolitis. We discuss our case with respect to the literature and highlight the current concepts in managing the treatment, given also the high risk of colorectal cancer (CRC).

Case report

A 14-year 1-month-old male, without any significant personal/family medical history, presented to our clinic in April 2006, with diffuse abdominal pain and bloody diarrhea (3-6 diurnal and nocturnal daily stools), for 16 days. He had been previously admitted into two hospitals and treated with antibiotics for presumed gastroenteritis, without any effect. In our clinic, the physical examination revealed pathologically pallor, palpebral edema, intense diffuse abdominal tenderness, palpable mass in the right lower paraumbilical area (~4/8 cm), with diminished abdominal sounds in that region, and bloody loose stools at the digital rectal examination. Somatic development was within the normal range (weight 46 kg, p10-25; height 161 cm, p50; BMI 17.7 kg/m², p10-25).

Clinically, the following hypotheses have been considered: persistent infectious diarrhea, antibiotic-associated diarrhea, inflammatory bowel disease or diverticulitis, associated with possible tumor.

Inflammatory markers were normal (ESR, fibrinogen, CRP, no neutrophilia). Basic blood tests have shown hypochromic microcytic hypsideremic anemia (Hb 10.3 g%, VEM: 75.5 fl, HEM: 24.5 pg, Fe=9 µg/dl) and hypoalbuminemia – 1.8g% [n 3.5-4.5 mg%]; liver, pancreatic, hemostasis and urinary tests were normal. Immunologic panel (including antinuclear antibodies, antidsDNA, serum immunoglobulins, pANCA, cANCA, ASCA) was normal. HIV, cytomegalovirus Ig M and Epstein-Barr virus Ig M antibodies were negative.

¹Second Pediatric Clinic, Emergency Children’s Hospital, Cluj-Napoca

²Department of Pathology, Emergency Children’s Hospital, Cluj-Napoca

³University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca

E-mail: danitiserban@yahoo.com

Neither pathogens nor dysbiosis were detected in the stool (including toxins against *Clostridium difficile*). On the next day, the patient's condition worsened, with insupportable abdominal pain. A colonoscopy was planned, but the surgeons suspected an ileo-colonic intussusception, requiring the patient to be transferred to their department. Two days later, a laparotomy was performed, however, without revealing any pathology. The patient was subsequently treated with antibiotics (Amikacin, Cefuroxime, Clindamycin), for an associated mandibular osteomyelitis and was dismissed from the surgery department 6 weeks later. In the hospital, as well as at home, he continued to present intermittent bloody diarrhea and abdominal pain. Readmitted in our clinic 2 months after the first visit, we found the same physical characteristics, except for the absence of the abdominal mass and the presence of weight loss (1 kg). Laboratory results were not much different than the first admission, except for the worsening of anemia (Hb 9.9 g %). Lower endoscopy revealed,

surprisingly, hundreds of diffuse colonic polyps, sized between 0.5 and 2 cm, most of them being sessile, with various shapes. The intervening mucosa (difficult to be appreciated given the density of polyps) showed erythema, loss of vascular pattern, ulcerations, friability and petechiae (Fig. 1). All lesions (including polyps) were much less pronounced in the rectum. Terminal ileum was normal. Upper digestive endoscopy was normal. The endoscopic diagnosis considered a diffuse colonic polyposis (with rectal sparing), inflammatory and/or adenomatous, in the settings of a possible active ulcerative colitis with relative rectal sparing. The histopathology report (a few days later) showed typical features of inflammatory polyposis (Fig. 2) and chronic active diffuse colitis, without any adenomatous feature. Our final diagnosis was moderate-to-severe ulcerative pancolitis, with diffuse GIP. A treatment with Prednisone and Salofalk was administered, according to the existing guidelines.




Fig. 1. Giant inflammatory polyposis coli in ulcerative colitis – colonoscopic features: multiple polyps, with various shapes, mostly sessile; the intervening mucosa (difficult to be appreciated because of the density of polyps) shows erythema, loss of vascular pattern, haemorrhage and ulcerations; a – sigmoid colon; b – transverse colon; c - descending colon; d – ascending colon.




Fig. 2. Inflammatory polyps in ulcerative colitis – microscopical features: protruding lesions consisting of regenerated mucosa, with areas of granulation tissue, covered by normal epithelium, without ulcerations.

One month later, the follow-up visit showed triple clinical, endoscopic and histological remission of the UC, with marked reduction in the number and size of the polyps. After tapering the steroids, 3 months later, colonoscopy showed remission of the UC, but with microscopical activity. To prevent the clinical flare-up, we restarted the steroid therapy, adding Azathioprine, given the steroid-dependency. The patient had 18 follow-up visits in our clinic (last in April 2010), with at least 2 colonoscopies/year. He remained in histological remission

for 5.6 years, with only a few diffuse scattered inflammatory polyps and a good somatic development (18 year-old male, weight 70 kg, p50-75; height 170 cm, p10-25; BMI 24.22 kg/m², p75-85). He did not develop any severe infection or side effects related to the therapy. Afterwards, he was transferred to an adult IBD clinic.

Discussions

Many aspects could be considered in this patient: the probable diagnosis at the first presentation - intestinal

intussusception due to GIP, with spontaneous resolution; the extreme rarity and also the severity of the diffuse GIP at the disease onset, with protein-losing enteropathy; the uselessness of the serological inflammatory markers in assessing the activity of the disease, contrasting with other reports⁷; the relative macroscopical rectal sparing (atypical in adult UC, but present in up to 30% of pediatric patients⁸); the patient's high risk of developing CRC; the crucial role of the colonoscopy in monitoring disease activity/surveillance for dysplasia and/or CRC.

Inflammatory polyps appear as intraluminal projections of inflamed or regenerated mucosa, covered by normal/ulcerated epithelium⁹. The classification of the inflammatory polyposis was made more than 30 years ago, considering the following types¹⁰: localized multiple polyposis (small polyps, < 5 mm with focal distribution), giant polyposis (large polyps, >1.5 cm, generally with focal distribution), generalized polyposis (small polyps with diffuse distribution) and filiform polyposis (elongated slender polyps, with diffuse or random distribution). Our case is peculiar, since he presented with a giant polyposis, but in a diffuse form, which is not included in the above classification.

An outstanding review of published cases with GIP in inflammatory bowel disease (1965-2007) found only 81 GIP in 78 patients¹, attesting the rarity of this entity. Moreover, as the authors stated, they had only 1 case in 10 years, out of 1921 patients with UC¹. GIP has been found to be very rare both at the CU onset (no case in children and 3 in adults, these all being localized⁴⁻⁶) and during the course of the disease (4 pediatric cases, 2 with total colectomy and 2 with partial colectomy, all being localized¹¹⁻¹⁴ and less than 40 cases in adults^{rev. in 1}). We believe that in our case the polyps were already expressed at the first admission, with protein-losing enteropathy and intestinal intussusception, which resolved spontaneously. This makes our case very intriguing, with respect to the very short time of developing the GIP (16 days). Even if we consider 2 months (until the colonoscopy), the period is still unusually short, most cases developing these polyps in years. That is why we considered also the possibility of another type of polyposis (e.g. adenomatous), superimposed on an active colitis. We found in the literature one case associating adenomatous polyposis coli and UC¹⁵, so that our supposition during the colonoscopy could have been right. In the classical differential diagnosis of the GIP, adenomatous polyp is included, but the main fear is that of an adenocarcinoma. Other entities to be excluded are dysplasia-associated lesion or mass and lesions secondary to cytomegalovirus or other infections¹.

Most cases with GIP had extensive UC, but with localized polyps – especially in the descending and transverse colon¹; there has been only one published case of pancolonic GIP in adults¹⁶. Our case is also unique in this respect in children, with GIP arising almost throughout the entire colon (only relative rectal sparing).

The clinical expression of GIP may appear as intestinal obstruction^{1,17}, intestinal intussusception², abdominal pain¹, diarrhea¹, lower hemorrhage¹, and abdominal palpable

mass¹. Three cases presented with protein-loss enteropathy^{13,16,18}, as was our patient.

We consider that monitoring this patient by periodic colonoscopy with biopsies (2-3/year) was the best choice, both for detecting the microscopical activity/remission and for the surveillance for dysplasia/CRC.

Indeed, if before 2005 the aim of the therapy in UC was to induce and maintain the clinical remission¹⁹, afterwards, the obtaining of the endoscopic mucosal healing started to be considered²⁰. Moreover, many clinicians have lately included as a therapeutic goal the achievement of the microscopical mucosal healing¹⁹. The detection of an active microscopical inflammation has been associated with a 2-3-fold increased risk of a clinical relapse after 1 year²¹. By performing colonoscopy in clinical remission, we were able to detect this microscopical activity of the UC and start a treatment that avoided the patient to have another clinical flare-up. By maintaining the microscopical remission of the disease, we consider that the risk of CRC was diminished^{19,22,23}, since a significant association between the degree of histological inflammation and progression towards CRC has been reported in the literature^{24,25}. Chronic inflammation increases oxidative stress, promotes repeated cycles of injury, regeneration, and repair, and accelerates the accumulation of oncogenic mutations²⁶. Conversely, especially in adult data, mucosal healing has been associated with long-term remission rates, reduction of disease-related complications and of hospitalization and surgery¹⁹, and this was true in our patient as well. Our patient was fortunate to keep the remission for such a long time, only with Salofalk and Azathioprine, with marked reduction in size and number of polyps, while most patients with GIP in IBD required colectomy (85%)¹. It is also true that very often surgery has been performed as a security precaution, given the possibility of the confusion of a GIP with an adenocarcinoma¹.

Nowadays, surrogates of the microscopical healing could be considered the fecal inflammatory markers, like calprotectin^{8,22}. According to the recent ECCO/ESPGHAN Consensus in pediatric UC, calprotectin levels >100-150 µg/g indicate mucosal inflammation, however its role in predicting clinical relapse needs to be further studied⁸. The same Consensus has stated that, in a patient in clinical remission, endoscopic evaluation is not routinely recommended, aside from cancer surveillance⁸. Investigation by inflammatory fecal parameters was not available at that time in our patient.

We highlight that, even if the colonic inflammation in our patient disappeared, he still has risk factors for developing dysplasia and CRC. Generally, in patients with UC, the relative risk of developing CRC is 5.7-fold increased compared with the general population²⁷. High risk factors include^{28,29}: young age at the UC onset, longstanding disease (cumulative risk of 1.6%, 8.3% and 18.4% after 10, 20 and 30 years of disease, respectively)³⁰, extensive colitis (relative risk 2 times higher)²⁷, family history of CRC (risk 2.5 times higher), inflammatory polyps (2-2.5-fold greater risk)^{31,32}, colonic strictures³¹, association with sclerosing cholangitis (relative risk 4.8-fold higher than in UC without

sclerosing cholangitis), severe endoscopic/histologic inflammation, detection of dysplasia. Protective factors include: normal colonoscopy^{24,31}, therapy with 5-aminosalicylates³³ (although recently controversial³⁴), therapy with Azathioprine³⁵ (but carrying a 4 times higher risk of developing lymphoma³⁶), therapy with ursodeoxycholic acid in those with sclerosing cholangitis^{28,29}, smoking (reduced risk by 50%)^{28,29} and prophylactic colectomy³⁷. Probable decreasing risk factors are adherence to therapy and surveillance colonoscopies (especially chromoendoscopy and endoscopy with magnification)^{28,29}. Given all this data, we consider that for the future, even if calprotectin is available, colonoscopic

surveillance is mandatory in our patient, in an adult clinic.

In *conclusion*, we have reported an unusual case presenting with short-time bloody diarrhea and abdominal pain, who was found with a palpable abdominal mass and was considered as having intestinal intussusception. The association of ulcerative pancolitis and diffuse GIP (expressed with protein-losing enteropathy) at the onset of the disease represents, to the best of our knowledge, the first case in the pediatric literature. The patient was closely monitored by colonoscopy with biopsies and was kept in long microscopical remission. The presence of factors increasing the risk of CRC requires a close follow-up of this patient in the adult clinic.

References

- Maggs JRL, Browning LC, Warren BF, Travis SPL. Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. *J Crohns Colitis* 2008; 2: 170-80.
- Esaki M, Matsumoto T, Fuyuno Y, et al. Giant inflammatory polyposis of the cecum with repeated intussusception in ulcerative colitis: report of a case. *Am J Gastroenterol* 2009; 104: 2873-4.
- Hinrichs HR, Goldman H. Localized giant pseudopolyps of the colon. *JAMA* 1968; 205: 248-9.
- Koinuma K, Togashi K, Konishi F, et al. Localized giant inflammatory polyposis of the cecum associated with distal ulcerative colitis. *J Gastroenterol* 2003; 38: 880-3.
- Munchar J, Rahman HA, Zawawi MM. Localized giant pseudopolyposis in ulcerative colitis. *Eur J Gastroenterol Hepatol* 2001; 13: 1385-7.
- Pilichos C, Preza A, Demonakou M, Kapatsoris D, Bouras C. Topical budesonide for treating giant rectal pseudopolyposis. *Anticancer Res* 2005; 25: 2961-4.
- Turner D, Mack DR, Hyams J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. *J Crohns Colitis* 2011; 5: 423-9.
- Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: a joint ECCO and ESPGHAN evidence-based consensus guidelines. *J Pediatr Gastroenterol Nutr* 2012 in press.
- Kelly JK, Gabos S. The pathogenesis of inflammatory polyps. *Dis Colon Rectum* 1987; 30: 251-4.
- Freeman AH, Berridge FR, Dick AP, Gleeson JA, Zeegen R. Pseudopolyposis in Crohn's disease. *Br J Radiol* 1978; 51: 782-7.
- Kirks DR, Currarino G, Berk RN. Localized giant pseudopolyposis of the colon. *Am J Gastroenterol* 1978; 69: 609-14.
- Adelson JW, de Chadarevian JP, Azouz EM, Guttman FM. Giant inflammatory polyposis causing partial obstruction and pain in "healed" ulcerative colitis in an adolescent. *J Pediatr Gastroenterol Nutr* 1988; 7: 135-40.
- Anderson R, Kaariainen IT, Hanauer SB. Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis. *Am J Med* 1996; 101: 323-5.
- Mandys V, Lukás M, Vernerová Z. A bizarre inflammatory polyposis of the colon in chronic ulcerative proctocolitis. *Cesk Patol* 1998; 34(2): 63-6.
- Brignola C, Belloli C, De Simone G, et al. Familial adenomatous polyposis and inflammatory bowel disease associated in two kindreds. *Dig Dis Sci* 1995; 40(2): 402-5.
- Bryan RL, Newman J, Alexander-Williams J. Giant inflammatory polyposis in ulcerative colitis presenting with protein losing enteropathy. *J Clin Pathol* 1990; 43: 346-7.
- Okayama N, Itoh M, Yokoyama Y, et al. Total obliteration of colonic lumen by localized giant inflammatory polyposis in ulcerative colitis: report of a Japanese case. *Intern Med* 1996; 35(1): 24-9.
- Koga K, Iida M, Aoyagi K, et al. Generalized giant inflammatory polyposis in a patient with ulcerative colitis presenting with protein-losing enteropathy. *Am J Gastroenterol* 1995; 90: 829-31.
- Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. *Inflamm Bowel Dis* 2010; 16(2): 338-46.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; 353: 2462-76.
- Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? *Gut* 1991; 32: 174-8.
- Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. *J Crohns Colitis* 2011; 5(5): 484-98.
- Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. *J Crohns Colitis*. 2011; 5(5): 477-83.
- Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 2004; 126: 451-9.
- Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic

- inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study, *Gastroenterology* 2007; 133: 1099–105.
26. Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. *J Clin Gastroenterol* 2003; 36: S70-74.
 27. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, MN. *Gastroenterology* 2006; 130:1039–46.
 28. Dassopoulos T. Update on colonic dysplasia and cancer in colitis. *Eur Gastroenterol Hepatol Rev* 2011; 7(1): 43–6.
 29. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. *Inflamm Bowel Dis* 2005; 11: 314-21.
 30. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; 48: 526–35.
 31. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. *Gut* 2004; 53: 1813–6.
 32. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. *Gastroenterology* 2006; 130: 1941–9.
 33. Velayos FS, Terdiman JP, Walsh JM, Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. *Am J Gastroenterol* 2005; 100: 1345–53.
 34. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. *Am J Gastroenterol* 2011; 106: 731-6.
 35. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. *Gut* 2012; 61(2): 235-40.
 36. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009; 374: 1617-25.
 37. Bergeron V, Vienne A, Sokol H, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. *Am J Gastroenterol* 2010; 105(11): 2405-11.

Correspondance to:

Elena Daniela Serban
 Second Pediatric Clinic
 Emergency Hospital for Children
 University of Medicine and Pharmacy “Iuliu Hatieganu”
 Cluj-Napoca
 Romania
 E-mail: danitiserban@yahoo.com